Valeant Pharmaceuticals Completes Acquisition of Dermik

MISSISSAUGA, Ontario, Dec. 19, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced that effective December 16, 2011, the company completed its previously announced acquisition of Dermik, a dermatology unit of Sanofi (EURONEXT: SAN andNYSE: SNY).

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Contact Information:
Laurie W. Little
949-461-6002
[email protected]

SOURCE Valeant Pharmaceuticals International, Inc.